African American men with prostate cancer have significantly lower PSA density than Caucasian men

A new study published in The Journal of Urology® revealed that African American men with Gleason score 3+3=6 prostate cancer (PCa) produce less prostate specific antigen (PSA) and have significantly lower PSA density (PSAD) than Caucasian men. These findings could have important implications when selecting patients for inclusion in active PCa surveillance programs. Read the article.

Australia PSA Testing Guideline Recommendations

In partnership with Cancer Council Australia and a multi-disciplinary expert advisory panel comprising urologists, medical oncologists, radiation oncologists, pathologists, general practitioners, epidemiologists, allied health professionals and consumers, Prostate Cancer Foundation of Australia has developed national evidence-based clinical practice guidelines on PSA testing and early management of test-detected prostate cancer. Read the article.

What Every Man Should Know About Prostate Cancer Screening

Prostate-specific antigen (PSA)-based screening for prostate cancer has long been controversial. With guidelines changing on a regular basis and experts disagreeing over its use, determining whether or not to get tested can be confusing. Arming yourself with a better understanding of the issues can guide your decision-making process. Read the article.

New Catalyst Yields More Accurate PSA Test

Discovery could, among other things, slash the numbers of false negatives in PSA tests. Xiaohu Xia and his team, including researchers from Louisiana State University and the University of Texas at Dallas, have developed a new catalyst that could make lab tests like the PSA much more sensitive. Read the article.

Advances in Prostate Cancer: 2014

The year 2014 has again provided important developments in the area of prostate cancer. New data and new treatments span the spectrum of prostate cancer management, from prevention and screening to optimal strategies for localized, locally advanced, and metastatic disease. Read the article.  (Free Medscape account required.)

Our Position on PSA Screening

In recent years, various task forces or panels have come out strongly against using the PSA blood test as a screening tool. The latest was the Canadian Task Force on Preventive Health Care (CTFPHC) which, on Monday October 27th, 2014 stated that this test should not be used, as it does not prove to save lives!

Scroll to Top